High blood pressure — hypertension — is the single most treatable risk factor for cardiovascular disease and stroke, the two leading causes of death in the United States. There are already more than a dozen classes of antihypertensive medications. For most patients, combining two or three of these drugs in appropriate doses achieves adequate blood pressure control and dramatically reduces the risk of heart attack, stroke, kidney failure, and premature death.
But for a significant subset — estimated at 10 to 15 percent of all hypertensive patients — blood pressure remains uncontrolled despite taking two, three, or even four medications at maximum tolerated doses. This is called resistant hypertension, and it represents one of the most clinically frustrating situations in internal medicine: a patient taking a handful of pills every day, experiencing their side effects, and still not achieving the blood pressure target that determines their future risk of cardiovascular catastrophe.
For these patients, the FDA’s May 18, 2026 approval of baxdrostat (Baxfendy) — developed by AstraZeneca — represents the arrival of a fundamentally new therapeutic option built on a mechanism of action that no previously approved drug has ever targeted in this indication.
«We have been waiting for an innovative medication like BAXFENDY for hypertension for many years,» said Bryan Williams, MD, Chair of Medicine at University College London and a primary investigator for the pivotal BaxHTN trial. «Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension.»
The Aldosterone Problem and Why Existing Drugs Miss It
Aldosterone is a steroid hormone produced by the adrenal glands that regulates sodium and water retention in the kidneys. When aldosterone levels are excessive — whether due to a benign adrenal tumor (primary aldosteronism), stress-related overproduction, or other dysregulation — the kidneys retain too much sodium and water, blood volume rises, and blood pressure increases in a way that does not respond well to most standard antihypertensive mechanisms.
The renin-angiotensin-aldosterone system (RAAS) is already a major target of existing hypertension drugs: ACE inhibitors, ARBs, and direct renin inhibitors all interfere with the pathway that leads to aldosterone production. But these drugs do not directly target aldosterone synthase — the specific enzyme, encoded by the CYP11B2 gene, that is the final step in aldosterone manufacturing in the adrenal gland. Blocking earlier steps in the RAAS leaves aldosterone synthase activity largely intact, allowing it to produce aldosterone through compensatory mechanisms.
Baxdrostat is a selective aldosterone synthase inhibitor — a small-molecule oral drug that directly and selectively inhibits CYP11B2, preventing aldosterone from being synthesized in the first place. This selectivity is critical: the enzyme CYP11B1, which produces cortisol and sits in a closely adjacent biochemical pathway, is not significantly affected by baxdrostat at therapeutic doses. This means baxdrostat lowers aldosterone — and therefore blood pressure — without disrupting the cortisol axis that regulates the stress response, immune function, and metabolism. AstraZeneca confirmed in clinical trials that baxdrostat lowered aldosterone levels without affecting cortisol levels.
What the BaxHTN Phase 3 Trial Found
The BaxHTN trial enrolled 796 patients with uncontrolled or resistant hypertension — all already on at least two antihypertensive agents, including a diuretic — and randomized them 1:1:1 to receive baxdrostat 2 mg once daily, baxdrostat 1 mg once daily, or placebo in addition to their background therapy, for 12 weeks.
At week 12:
- Patients on baxdrostat 2 mg had a 15.7 mmHg reduction in seated systolic blood pressure from baseline — a 9.8 mmHg placebo-adjusted reduction.
- Patients on baxdrostat 1 mg had a 14.5 mmHg reduction — an 8.7 mmHg placebo-adjusted reduction.
- The placebo group had a 5.8 mmHg reduction from baseline.
Both doses met the primary endpoint of statistically significant systolic blood pressure reduction. The findings were consistent in patients with both uncontrolled hypertension (not at goal despite two or more drugs) and truly resistant hypertension (not at goal despite three or more drugs, including a diuretic). Results were also supported by a separate Phase 3 Lancet-published Bax24 trial using ambulatory blood pressure monitoring, confirming the effect on 24-hour blood pressure rather than only the clinic reading.
A 9.8 mmHg reduction in systolic blood pressure is not a cosmetic number. Systematic reviews of blood pressure interventions consistently show that each 5 mmHg reduction in systolic blood pressure reduces the risk of major cardiovascular events by approximately 10 percent. For patients whose blood pressure has been inadequately controlled despite multiple medications — meaning they have been living with elevated cardiovascular risk despite treatment — a nearly 10 mmHg additional reduction is clinically meaningful and potentially life-extending.
Who Will Benefit and What Comes Next
Baxfendy is approved as an add-on oral treatment for adults with hypertension not adequately controlled on other medications. It is taken once daily in 1 mg or 2 mg doses. The key safety considerations identified in trials are hyperkalemia (elevated blood potassium), which requires periodic monitoring, and hyponatremia (low sodium) in some patients. Neither was dose-limiting in the vast majority of trial participants.
The drug received Fast Track and Breakthrough Therapy designations from the FDA during development, signaling the agency’s recognition of the unmet need it addresses. AstraZeneca is also studying baxdrostat in additional conditions where aldosterone excess plays a mechanistic role, including chronic kidney disease and heart failure — conditions that frequently co-occur with resistant hypertension.
Frequently Asked Questions
Q: What is baxdrostat (Baxfendy) and who is it for?
A: Baxdrostat is the first-ever oral aldosterone synthase inhibitor, FDA-approved May 18, 2026 as an add-on treatment for adults with hypertension not adequately controlled on other antihypertensive medications.
Q: How does baxdrostat work differently from other blood pressure drugs?
A: It directly and selectively inhibits aldosterone synthase (the CYP11B2 enzyme), preventing aldosterone production at its source. No previously approved drug has targeted this specific enzyme. Existing RAAS drugs act earlier in the pathway and leave aldosterone synthase partially active.
Q: How much does baxdrostat lower blood pressure?
A: In the BaxHTN Phase 3 trial, baxdrostat 2 mg added to background therapy produced a 9.8 mmHg placebo-adjusted reduction in systolic blood pressure at 12 weeks. The 1 mg dose achieved an 8.7 mmHg reduction.
Q: Does baxdrostat affect cortisol levels?
A: No. Baxdrostat selectively inhibits CYP11B2 (aldosterone synthase) without significantly affecting CYP11B1 (cortisol synthesis). Clinical trials confirmed aldosterone reductions without changes in cortisol.
Q: What are the main side effects of baxdrostat?
A: Hyperkalemia (elevated potassium) and hyponatremia (low sodium) are the primary safety considerations, both requiring periodic monitoring. Neither was dose-limiting in most trial participants.
